On August 5, Charles River Laboratories rose 8.32% in regular trading, trading at $257.465/share, with turnover of $35.13 million. The rally was driven by the company's second-quarter earnings report that comprehensively exceeded market expectations.

Charles River reported Q2 adjusted EPS of $3.02, beating the analyst consensus estimate of $2.74 by approximately 10.2%. Revenue came in at $1.004 billion, surpassing the FactSet estimate of $975.7 million. The market had previously adopted a cautious stance on the quarter, expecting a modest year-over-year revenue decline. The company simultaneously raised its full-year adjusted EPS guidance to $11.15–$11.45, up from the prior range of $10.80–$11.30 and above the FactSet consensus of $11.11. Management noted that demand improvement trends have been broad-based across global client segments, validating the market's optimistic view on accelerating second-half performance. This marks the second consecutive quarter of earnings beats, following a Q1 adjusted EPS of $2.06 that also exceeded estimates, reinforcing confidence in the company's recovery trajectory.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)